Orgenesis Provides Year End Business Update
April 15, 2024 17:07 ET
|
Orgenesis Inc.
Major transformation underway commencing with recent acquisitionreasserting full ownership and control over Octomera Secured a $2.3 million investment from a group including sophisticated healthcare...
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
April 10, 2024 12:00 ET
|
Orgenesis Inc.
ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global...
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
March 18, 2024 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced...
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
March 13, 2024 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced...
Orgenesis Inc. Announces $2.3 Million Private Placement
March 04, 2024 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), announced today...
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
February 29, 2024 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that...
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
January 31, 2024 09:15 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced it...
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
November 14, 2023 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Provides Business Update for the Third Quarter of 2023
November 13, 2023 16:15 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
November 08, 2023 09:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (“Orgenesis”) (Nasdaq: ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs),...